Reyvow
- Product NDC
- 0002-4312
- 11-digit product format
- 000024312
- Labeler code
- 0002
- Product ID
- 0002-4312_75a13e98-3736-4256-8277-6c05bcaddcf5
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- lasmiditan
- Dosage form
- TABLET
- Route
- ORAL
- Labeler
- Eli Lilly and Company
- Application
- NDA211280
- Marketing category
- NDA
- Marketing start
- 2019-10-11
- Substance
- LASMIDITAN
- Active strength
- 50 mg/1
- DEA schedule
- CV
- NDC exclude flag
- No
- Listing certified through
- 2026-12-31
- Current FDA listing
- Yes
Additional Listing Data#
- Finished product
- Yes
- Brand name base
- Reyvow
- Listing expiration
- 2026-12-31
Active Ingredients#
Ingredient, Strength table| Ingredient | Strength |
|---|
| LASMIDITAN | 50 mg/1 |
Harmonized Identifiers#
Field, Values table| Field | Values |
|---|
| Unii | 760I9WM792 |
| Rxcui | 2256937, 2256943, 2256945, 2256947 |
DailyMed Product Concepts#
DailyMed Package Descriptions#
DailyMed Dashboard NDC Coverage#
NDC, Dashboard title, SPL version table| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|
| 0002-4312 | REYVOW (LASMIDITAN) TABLET [ELI LILLY AND COMPANY] | 15 | Current NDC, Legacy NDC, 6 package rows | 20241215_aea3358c-ff41-4490-9e6d-c7bf7b3de13f.zip |
DailyMed RxNorm Mappings#
Packages#
Package NDC, 11-digit format, Description table| Package NDC | 11-digit format | Description | Units | Marketing start | Marketing end | Sample | Exclude flag | Status |
|---|
| 0002-4312-08 | 00002431208 | 2 BLISTER PACK in 1 CARTON (0002-4312-08) / 4 TABLET in 1 BLISTER PACK | 2 blister pack | 2020-01-31 | 0000-00-00 | No | No | Current |
| 0002-4312-61 | 00002431261 | 1 BLISTER PACK in 1 CARTON (0002-4312-61) / 4 TABLET in 1 BLISTER PACK | 1 blister pack | 2021-03-03 | 0000-00-00 | Yes | No | Current |
| 0002-4312-62 | 00002431262 | 1 BLISTER PACK in 1 CARTON (0002-4312-62) / 2 TABLET in 1 BLISTER PACK | 1 blister pack | 2022-02-28 | 0000-00-00 | Yes | No | Current |